E
Eduard Gorina
Researcher at Genentech
Publications - 17
Citations - 2847
Eduard Gorina is an academic researcher from Genentech. The author has contributed to research in topics: FEV1/FVC ratio & Idiopathic pulmonary fibrosis. The author has an hindex of 7, co-authored 16 publications receiving 2511 citations.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Dinesh Khanna,Carlo Albera,Aryeh Fischer,Nader Khalidi,Ganesh Raghu,Lorinda Chung,Dan Chen,Elena Schiopu,Margit Tagliaferri,James R. Seibold,Eduard Gorina +10 more
TL;DR: Pfenidone showed an acceptable tolerability profile in SSc-ILD, although a longer titration may be associated with better tolerability, and exploratory disease outcomes remained largely unchanged.
Journal ArticleDOI
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Luca Richeldi,Evans R. Fernández Pérez,Ulrich Costabel,Carlo Albera,David J. Lederer,Kevin R. Flaherty,Neil Ettinger,Rafael Perez,Mary Beth Scholand,Jonathan G. Goldin,Kin-Hung Peony Yu,Thomas B. Neff,Seth Porter,Ming Zhong,Eduard Gorina,Elias Kouchakji,Ganesh Raghu +16 more
TL;DR: Pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis and was well tolerated, with a safety profile similar to that of placebo.
Journal ArticleDOI
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Carlo Albera,Ulrich Costabel,Elizabeth A. Fagan,Marilyn K. Glassberg,Eduard Gorina,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Dominique Spirig,Jeffrey J. Swigris +9 more
TL;DR: Findings support the initiation of treatment with pirfenidone, irrespective of stage of baseline lung function in this patient population, as efficacious in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Journal ArticleDOI
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.
Johan Clukers,Maarten Lanclus,Benjamin Mignot,C. Van Holsbeke,J. Roseman,Seth Porter,Eduard Gorina,Elias Kouchakji,K. E. Lipson,W. De Backer,J. De Backer +10 more
TL;DR: This study indicates that FRI is a superior tool than FVC in capturing of early and clinically relevant, disease progression in a regional manner.